Anzeige
Mehr »
Login
Freitag, 14.05.2021 Börsentäglich über 12.000 News von 658 internationalen Medien
InnoCan Pharma liefert echte Sensation ab!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
211 Leser
Artikel bewerten:
(0)

SHIRE PLC: Final Results

Hampshire International Business Park                                          
Chineham Basingstoke                                                           
Hampshire RG24 8EP                                                             
United Kingdom                                                                 
Tel +44 (0)1256 894000                                                         
Fax +44 (0)1256 894708                                                         
www.shire.com                                                                  
                                                                               
Press Release                                                                  

11.00 am GMT 6am EST

     On time execution of operating plan delivers strong 2006 performance      

 SHIRE AGREES TO ACQUIRE NEW RIVER TO GAIN FULL CONTROL OF VYVANSE, ITS FUTURE 
                           FLAGSHIP PRODUCT FOR ADHD                           

     All cash transaction for $2.6 billion funded by $2.3 billion new debt     
                                facilities and                                 

                        $800 million equity financing.                         

Basingstoke, UK - February 20, 2007 - Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX:
SHQ) announces results for the twelve months to December 31, 2006 - a year in
which significant milestones were met, providing long-term drivers for the
future growth of the Company. In addition, Shire announces in a separate press
release that it has agreed to acquire New River Pharmaceuticals Inc (New River)
for $2.6 billion in cash funded by $2.3billion new debt facilities and
approximately $800 million of equity financing, a move that will increase the
value of its leadership in the US Attention Deficit and Hyperactivity Disorder
(ADHD) market.

2006 Financial Highlights

  * Product sales up 16% to $1,536 million;
   
  * Total revenues up 12% to $1,797 million;
   
  * Cash and cash equivalents up $470 million;
   
  * Dividends up 15%.
   
Matthew Emmens, Chief Executive Officer, said:

"2006 was an exceptional year for Shire in which we increased our strong
leadership position in the US ADHD market and successfully executed all our
planned regulatory filings and new product launches. We delivered good
financial results, including a 12% rise in revenues and strong cash generation.

"This is an important and complementary acquisition that gives us full control
of VYVANSE, a novel drug. We are confident and expect that the final labeling
will provide patients and physicians with real benefits that differentiate this
compound from other ADHD products. It will enable us to drive the launch and
future development of VYVANSE and gain the full economic benefits of the drug.
Based on VYVANSE's expected profile, we believe it has the potential to be the
next generation stimulant product to ADDERALL XR®. This acquisition continues
our leadership position in the growing US ADHD market, improves our operating
margins, significantly enhances our earnings growth from late 2009 and delivers
on our overall global growth strategy. The combined debt and equity financing
announced today enables us to both acquire New River and retain the financial
flexibility to make further acquisitions that will continue to drive Shire's
growth."

Looking ahead, in 2007 we expect to see the positive impact of our strategic
plan put in place three years ago. We will benefit from the recent launches of
DAYTRANA™ and ELAPRASE™ and roll-out of FOSRENOL® in Europe and anticipate
three additional product launches during the first half of the year namely
LIALDA™ / MEZAVANT™, VYVANSE™ and DYNEPO®. This year should also see the
approval of SPD465 and SPD503 for ADHD. In addition, we have added nine new
products into our development pipeline, including three new HGT (Human Genetic
Therapies) products.

Shire continues to look at ways in which it can effectively apply its cash flow
to generate long-term shareholder value through strengthening its pipeline of
specialty products with long lifecycles and strong intellectual property."

2006 Product highlights

  * ADDERALL XR - ADHD - Sales for 2006 up 18% to $864 million.
   
  * DAYTRANA - ADHD - Approved by the Food and Drug Administration (FDA) in
    April 2006 and launched in the US in June 2006. By December 31, 2006
    DAYTRANA had a 2% share of the US ADHD market and had achieved sales of $25
    million.
   
  * ELAPRASE - Hunter syndrome
   
  * Launched in the US in August 2006 and by December 31, 2006 over 110
    patients in the US had received treatment.
   
  * EU pre-approval process commenced in July 2006. By December 31, 2006 over
    100 patients were receiving treatment on a named-patient basis.
   
  * Sales for 2006 of $24 million.
   
  * REPLAGAL® - Fabry disease - Sales for 2006 up 24% to $118 million.
   
  * FOSRENOL - Hyperphosphatemia
   
  * 
      + Prescription growth of 34% in the US. While US net sales were down 16%,
        this was due to significant stocking of higher strength formulations at
        the end of 2005.
       
      + Sales in Europe reached $4.6 million.
       
      + In October 2006, Health Canada granted a marketing license application
        for FOSRENOL. Launch in Canada is planned for Q2 2007.
       
2006 Pipeline highlights

  * VYVANSE (NRP104) - ADHD - New River received a second approvable letter
    from the FDA on December 21, 2006. Shire expects New River to receive the
    FDA's final response by February 24, 2007 with launch for the pediatric
    indication still expected for Q2 2007, pending final scheduling
    discussions.
   
  * SPD465 - ADHD - Filed with the FDA in July 2006. The Prescription Drug User
    Fee Act (PDUFA) date is May 21, 2007.
   
  * SPD503 - ADHD - Filed with the FDA in August 2006. The PDUFA date is June
    24, 2007.
   
  * GA-GCB - Gaucher disease - Phase 3 clinical program initiated and enrolment
    began in January 2007.
   
  * Shire Human Genetic Therapies (HGT) - Three projects advanced to
    pre-clinical development; namely enzyme replacement therapies for
    Sanfilippo syndrome (Mucopolysaccharidosis IIIA), Metachromatic
    Leukodystrophy and intrathecal delivery of ELAPRASE for Hunter syndrome
    patients with significant central nervous system symptoms.
   
  * SPD491 - A once-a-day, non opiate, transdermal analgesic being developed
    with the goal of non-scheduled labeling to treat moderate to severe pain,
    will enter Phase 1 testing in Q1 2007.
   
  * SPD535 - Pre-clinical evaluation for development of a novel
    platelet-lowering agent.
   
In addition we in-licensed:

  * Rights to the transvaginal ring technology of Duramed Pharmaceuticals Inc.
    (Duramed) in the larger European markets in August 2006, together with a
    license in the same countries to Duramed's oral contraceptive, SEASONIQUE®
    (levonorgestrel/ethinyl estradiol).
   
  * Global rights to SPD500 (Tissue Protective Cytokine Technology), from
    Warren Pharmaceuticals, Inc. (Warren) in September 2006. SPD500 is being
    developed pre-clinically in non-nervous system indications, including renal
    and genetic disease areas.
   
  * Global rights to SPD493 (Valrocemide) and other related compounds, from
    Yissum Research and Development Company in July 2006. SPD493 is being
    developed at Phase 1 for the treatment of a number of central nervous
    system disorders.
   
2006 Business Highlights

  * All pending patent infringement litigations with Impax Laboratories Inc.
    (Impax) and Barr Laboratories Inc. (Barr) in connection with ADDERALL XR
    were settled in January 2006 and August 2006, respectively.
   
  * Repayment by IDB Biomedical Inc (IDB) of its loan for flu development ($71
    million plus interest of $8 million) in February 2006.
   
  * ADDERALL® (immediate-release mixed amphetamine salts) was sold to Duramed
    for $63 million in August 2006.
   
  * FOSRENOL - Hyperphosphatemia. Agreement with Abbott Laboratories (Abbott)
    signed in December 2006 for the co-promotion of FOSRENOL in the US. 
    Abbott's US renal care sales team will co-promote FOSRENOL with Abbott's
    Vitamin D product ZEMPLAR®.  Shire's US renal sales force will also
    continue to promote FOSRENOL.  Abbott's co-promotion activities began in Q1
    2007 and will continue for a term of five years.
   
Recent Developments

  * Shire agrees to acquire New River for $2.6 billion in an all cash tender
    offer and merger and raises approximately $800 million in equity financing.
    For details see separate release.
   
  * ELAPRASE - Marketing authorisation granted by the European Medicines Agency
    on January 8, 2007. Pricing and reimbursement procedures are underway in
    many EU countries and launch is expected across the majority of EU
    countries in 2007.
   
  * LIALDA - Ulcerative Colitis. Approval received from the FDA on January 16,
    2007. US launch is planned for Q1 2007.
   
  * SPD754 - HIV. Shire licensed the US and Canadian rights for the
    investigational HIV compound, SPD754 (also known as apricitabine), to the
    Australian biotechnology company Avexa Limited (Avexa) on January 23, 2007.
    Shire received an up-front cash payment of US$10 million, 8 million
    additional Avexa shares (taking its shareholding in Avexa to just over 8%)
    and may receive further milestones and royalties. 
   
  * MEZAVANT XL - Ulcerative Colitis. UK national licence received from the
    Medicines and Healthcare Products Regulatory Agency on January 19, 2007.
   
  * ADDERALL XR - Health Canada granted a marketing license application for the
    adult indication in February 2007.
   
  * FOSRENOL - Launched in the UK on February 19, 2007.
   
  * REPLAGAL - To launch in Japan with partner Dainippon Sumitomo Pharma Co.,
    Ltd by the end of Q1 2007.
   
Non-Executive Director Changes

  * July 2006 - Kate Nealon joined the Shire board as a Non-Executive Director
    and a member of the Remuneration Committee. Kate Nealon was Group Head of
    Legal & Compliance at Standard Chartered plc until 2004. She also holds
    Non-Executive Director positions with HBOS and Cable and Wireless plc.
   
  * December 2006 - Mr Ronald Nordmann stepped down from Shire's Board after
    seven years of service following expiry of his term of office.
   
  * January 2007 - Dr Jeffrey M. Leiden, MD, PhD joined Shire's board as a Non
    Executive Director. Dr Leiden served as President and Chief Operating
    Officer, Pharmaceutical Products Group and Chief Scientific Officer at
    Abbott Laboratories from 2001-2006.
   
Full Year 2006 Unaudited Results

                                2006                           2005              
                                                                                 
                   US GAAP Adjustments  Non GAAP  Restated  Restated    Non GAAP 
                                          (1)     US GAAP  Adjustments    (1)    
                     $M        $M                    $M                          
                                           $M                  $M          $M    
                                                                                 
                   _______  __________ __________  _______  __________ __________
                                                                                 
Revenues           1,796.5           -    1,796.5  1,599.3           -    1,599.3
                                                                                 
Income/(loss) from   316.8        70.1      386.9  (491.7)       926.9      435.2
ongoing operations                                                               
(2)                                                                              
                                                                                 
Net income/(loss)    278.2        10.7      288.9  (578.4)       892.4      314.0
                                                                                 
Diluted earnings/                                                                
(losses) per:                                                                    
                                                                                 
Ordinary share       54.6c        2.1c      56.7c (115.6c)      178.2c      62.6c
                                                                                 
ADS                 163.8c        6.3c     170.1c (346.8c)      534.6c     187.8c
                                                                                 

Q4 2006 Unaudited Results

                              Q4 2006                        Q4 2005            
                                                                                
                   US GAAP Adjustments   Non GAAP US GAAP Adjustments   Non GAAP
                                              (1)                            (1)
                        $M          $M                 $M          $M           
                                               $M                             $M
                                                                                
                   _______   _________ __________ _______  __________ __________
                                                                                
Revenues             497.0           -      497.0   464.9           -      464.9
                                                                                
Income from           90.3         1.7       92.0   101.0        27.3      128.3
ongoing operations                                                              
(2)                                                                             
                                                                                
Net Income            68.6         1.2       69.8    69.0        20.6       89.6
                                                                                
Diluted earnings                                                                
per:                                                                            
                                                                                
Ordinary share       13.4c        0.2c      13.6c   13.7c        4.1c      17.8c
                                                                                
ADS                  40.2c        0.6c      40.8c   41.1c       12.3c      53.4c
                                                                                
Note: Average exchange rates for 2006 and 2005 were $1.84: £1.00 and $1.82: £   
1.00, respectively. Average exchange rates for Q4 2006 and Q4 2005 were $1.92:  
£1.00 and $1.75: £1.00, respectively.                                           

(1)For an explanation of why Shire's management believes that these non-GAAP
financial measures are useful to investors, see page 7.  For a reconciliation
of these non-GAAP financial measures to the most directly comparable financial
measures prepared in accordance with US GAAP, see pages 26-27.

(2) Income/(loss) from continuing operations before income taxes and equity in
earnings/(losses) of equity method investees.

Restatement of 2005 US GAAP Results

The Company today announces the restatement of its financial statements for the
year to December 31, 2005, in respect of the value ascribed to in-process
research and development (IPR&D), acquired as part of the Transkaryotic
Therapies, Inc. (TKT) acquisition and subsequently written off as required
under US GAAP in Q3, 2005. IPR&D represented those assets which, at the time of
the acquisition, had not been approved by the FDA or other regulatory
authorities, including I2S (now known as ELAPRASE) and GA-GCB.

The Company has determined that the value ascribed to IPR&D acquired as a
result of the TKT acquisition did not include the benefit of tax amortization
as required by the American Institute of Certified Public Accountants (AICPA)
Practice Aid, Assets Acquired in a Business Combination to Be Used in Research
and Development Activities: A Focus on Software, Electronic Devices, and
Pharmaceutical Industries. The effect of this omission was to understate the
value of IPR&D expensed in the year to December 31, 2005 by $142 million, with
a corresponding overstatement of goodwill as at December 31, 2005.

However, as the additional IPR&D write-off in the year ended December 31, 2005
is a non-cash accounting item, it has no impact on the cash flows of the
Company for the year ended December 31, 2005. In addition, it has no impact on
the cash flows or earnings of the Company for the year ended December 31, 2006
or beyond.

The results for the year to December 31, 2005 have been restated to record the
value of IPR&D written off in Q3 2005 at $815 million (previously $673
million). As a result of this restatement the net loss as reported under US
GAAP for the year to December 31, 2005 has increased from $436.4 million to
$578.4 million, with the diluted loss per ordinary share as reported under US
GAAP for the year to December 31, 2005 increasing from 87.2 cents to 115.6
cents per ordinary share.

Non-GAAP income from continuing operations of $435.2 million, net income of
$314.0 million and diluted earnings per ordinary share of 62.6 cents (187.8
cents per ADS), for the year to December 31, 2005, are unaffected by this
restatement.

2007 Outlook

R&D pipeline and new product launches

Shire has a strong product pipeline to support the future growth of the
Company. In 2007 and H1 2008, the following launches are planned:

  * VYVANSE in the US;
   
  * ELAPRASE in Europe;
   
  * LIALDA in the US and MEZAVANT in Europe;
   
  * FOSRENOL in the UK, Spain and Italy;
   
  * DYNEPO in Europe; and
   
  * REPLAGAL in Japan by Shire's partner Dainippon Sumitomo Pharmaceuticals,
    Inc.
   
In addition, Shire is anticipating FDA decisions on:-

  * SPD503 for ADHD in the US; and
   
  * SPD465 for ADHD in the US.
   
Timings of approvals and launches are subject to the regulatory/governmental
approvals process.

Financial Outlook

This outlook excludes the impact of the New River acquisition.

Shire's business continues to perform strongly. We expect 2007 revenue growth
to be around 20% (assuming prescription growth in the ADHD market of 4-6%).

As in 2006, earnings for 2007 will continue to be impacted by the costs
associated with the continued development and launch of new products. We
anticipate that up to six new products will be launched during 2007 and H1 2008
in addition to the expected continued growth of DAYTRANA, ELAPRASE and FOSRENOL
in the US and ELAPRASE and FOSRENOL in Europe.

  * These launches will require additional advertising and promotional spend
    and in some cases additional sales representatives. Consequently, SG&A
    costs are expected to rise to between $930 - 960 million for 2007;
   
  * Phase 3(b) and Phase 4 studies to support new product launches and the
    continuation of Phase 3 trials on GA-GCB, the development of the Women's
    Health franchise, pre-clinical development of three HGT projects and two
    new Phase 1 projects and two further pre-clinical projects, are all
    expected to result in R&D spend in the range of $360 - 380 million;
   
  * The depreciation charge for the year is expected to increase by
    approximately 20% compared to 2006; and
   
  * The effective tax rate for 2007 is expected to be approximately 26%.
   
In 2007 Shire intends to commence reporting its non-GAAP earnings based on
adjusted EPS, which will exclude amortisation charges and the accounting impact
of SFAS123R for share based compensation. Consequently the financial outlook
for the full year stated above excludes amortisation charges, which are
expected to rise by 20% over 2006 and the accounting impact of SFAS123R
estimated at approximately $45m, which will be split for GAAP purposes between
cost of goods, R&D and SG&A in the approximate ratio of 10%, 20% and 70%,
respectively.

Dividend

In respect of the six months to December 31, 2006 the Board has resolved to pay
a second interim dividend of 5.2455 US cents per ordinary share (2005: 4.419 US
cents per share). Together with the first interim payment of 1.9346 US cents
per ordinary share (2005: 1.8246 US cents per share), this represents total
dividends for 2006 of 7.1801 US cents per share (2005: 6.2436 US cents per
share), an increase of 15% in US Dollar terms over 2005.

Dividend payments will be made in Pounds Sterling to Ordinary Shareholders, US
Dollars to ADS holders and Canadian Dollars to Exchangeable Shareholders. A
dividend of 2.6933 pence per ordinary share, 15.7365 US cents per ADS and an
amount in Canadian cents per Exchangeable Share, to be determined based on the
February 20, 2007 noon rate of the Bank of Canada, respectively will be paid.
The Board has resolved to pay the dividend on April, 5, 2007 to persons whose
names appear on the register of members of the Company (or to persons
registered as holders of Exchangeable Shares in Shire Acquisition Inc.) at the
close of business on March 16, 2007.

Shire intends to pursue a progressive dividend policy.

New Accounting Standard - SFAS 123R

Shire's primary basis of financial reporting is US GAAP. From January 1, 2006
Shire has applied SFAS 123R in accounting for share-based compensation. This
accounting standard applies a fair value methodology in quantifying the
accounting charge associated with share-based compensation.

The Company has adopted SFAS 123R according to the modified retrospective
method. As a result, comparatives, including accounting periods in 2005, have
been retrospectively adjusted.

For further information please contact:

Investor Relations Cléa Rosenfeld (Rest of the World)      +44 1256 894 160
                                                                           
                   Brian Piper (North America)              +1 484 595 8252
                                                                           
                   Eric Rojas (North America)               +1 484 595 8252
                                                                           
Media              Jessica Mann (Rest of the World)        +44 1256 894 280
                                                                           
                   Matthew Cabrey (North America)           +1 484 595 8248

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty pharmaceutical
company that focuses on meeting the needs of the specialist physician. Shire
focuses its business on ADHD, human genetic therapies (HGT), gastrointestinal
(GI) and renal diseases. The structure is sufficiently flexible to allow Shire
to target new therapeutic areas to the extent opportunities arise through
acquisitions. Shire believes that a carefully selected portfolio of products
with a strategically aligned and relatively small-scale sales force will
deliver strong results.

Shire's focused strategy is to develop and market products for specialty
physicians. Shire's in-licensing, merger and acquisition efforts are focused on
products in niche markets with strong intellectual property protection either
in the US or Europe.

For further information on Shire, please visit the Company's website: 
www.shire.com

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT
OF 1995

Statements included herein that are not historical facts are forward-looking
statements. Such forward-looking statements involve a number of risks and
uncertainties and are subject to change at any time. In the event such risks or
uncertainties materialise, Shire's results could be materially affected. The
risks and uncertainties include, but are not limited to: risks associated with
the inherent uncertainty of pharmaceutical research, product development,
manufacturing and commercialisation; the impact of competitive products,
including, but not limited to the impact of those on Shire's ADHD franchise;
patents, including but not limited to, legal challenges relating to Shire's
ADHD franchise; government regulation and approval, including but not limited
to the expected product approval dates of SPD503 (guanfacine extended release)
(ADHD), SPD465 (extended release of mixed amphetamine salts) (ADHD), and
VYVANSE (NRP104) (lisdexamfetamine dimesylate) (ADHD), including its scheduling
classification by the Drug Enforcement Administration in the United States;
Shire's ability to complete, and achieve anticipated benefits from the
acquisition of New River; Shire's ability to secure new products for
commercialisation and/or development; and other risks and uncertainties
detailed from time to time in Shire's filings with the Securities and Exchange
Commission.

Non-GAAP Measures

This press release contains financial measures not prepared in accordance with
US GAAP. These measures are referred to as "non GAAP" measures and include Non
GAAP income from ongoing operations, Non GAAP net income, Non GAAP diluted
earnings per ordinary share and Non GAAP diluted earnings per ADS. These non
GAAP measures exclude the effect of certain cash and non-cash items, both
recurring and non-recurring, that Shire's management believes are not related
to the ongoing performance of Shire's business.

These non GAAP financial measures are used by Shire's management to make
operating decisions because they facilitate internal comparisons of the
Company's performance to historical results and to competitors' results. These
measures are also considered by the Remuneration Committee of Shire's Board of
Directors in assessing the performance and compensation of employees, including
its executive officers.

The non GAAP measures are presented in this press release as the Company's
management believe that they will provide investors with a means of evaluating,
and an understanding of how Shire's management evaluates, the Company's
performance and results on a comparable basis that is not otherwise apparent on
a GAAP basis, since many one-time or infrequent items that the Company's
management believe are not indicative of the ongoing performance of the
business may not be excluded when preparing financial measures under US GAAP.

However, these non GAAP measures should not be considered in isolation from, as
substitutes for, or superior to financial measures prepared in accordance with
US GAAP.

Additional Information

The tender offer described in this press release has not yet commenced, and
this press release is neither an offer to purchase nor a solicitation of an
offer to sell New River common stock. Investors and security holders are urged
to read both the tender offer statement and the solicitation/recommendation
statement regarding the tender offer described in this report when they become
available because they will contain important information. The tender offer
statement will be filed by a subsidiary of Shire with the Securities and
Exchange Commission (SEC), and the solicitation/recommendation statement will
be filed by New River with the SEC. Investors and security holders may obtain a
free copy of these statements (when available) and other documents filed by
Shire or New River with the SEC at the website maintained by the SEC at
www.sec.gov. The tender offer statement and related materials may be obtained
for free by directing such requests to Shire at Hampshire International
Business Park, Chineham, Basingstoke, Hampshire, England, RG24 8EP, attention:
Investor Relations. The solicitation/recommendation statement and such other
documents may be obtained by directing such requests to New River at 1881 Grove
Avenue, Radford, Virginia 24141, attention: Director of Corporate
Communications.

The following are trademarks of Shire or companies within the Shire Group which
are the subject of trademark registrations in certain territories:

ADDERALL XR® (mixed salts of a single-entity amphetamine)
ADDERALL® (mixed salts of a single-entity amphetamine)
AGRYLIN® (anagrelide hydrochloride)
CALCICHEW® range (calcium carbonate with or without vitamin D3)
CARBATROL® (carbamazepine extended-release capsules)
COLAZIDE® (balsalazide)
DAYTRANA™ (methylphenidate transdermal system)
ELAPRASE™ (idursulfase)
FOSRENOL® (lanthanum carbonate)
GENE-ACTIVATED®

LIALDA™ (mesalamine)

LODINE ® (etodolac)
MEZAVANT ™ (mesalamine)
REMINYL® (galantamine hydrobromide) (UK and Republic of Ireland)
REMINYL XL™ (galantamine hydrobromide) (UK and Republic of Ireland)
REPLAGAL® (agalsidase alfa)
SOLARAZE® (3%, gel diclofenac sodium (3%w/w))
VANIQA® (eflornithine hydrochloride)
VYVANSE™ (lisdexamfetamine dimesylate)

XAGRID® (anagrelide hydrochloride)

The following are trademarks of third parties referred to in this press release
:

3TC (trademark of GlaxoSmithKline (GSK))
DYNEPO (trademark of Sanofi Aventis)
MMX Multi Matrix Systems (trademark of Cosmo Technologies Limited)
PENTASA (trademark of Ferring)
RAZADYNE (trademark of Johnson & Johnson)
RAZADYNE ER (trademark of Johnson & Johnson)
REMINYL (trademark of Johnson & Johnson, excluding UK and Republic of Ireland)
REMINYL XL (trademark of Johnson & Johnson, excluding UK and Republic of
Ireland)
SEASONIQUE (trademark of Barr Laboratories, Inc.)
ZEFFIX (trademark of GSK)

ZEMPLAR (trademark of Abbott Laboratories)

OVERVIEW OF US GAAP FINANCIAL RESULTS

1. Introduction

Summary of 2006

Revenues from continuing operations for the year to December 31, 2006 increased
by 12% to $1,796.5 million (2005: $1,599.3 million).

Income from continuing operations (before income taxes and equity in earnings/
(losses) of equity method investees) for the year to December 31, 2006 was
$316.8 million (2005: loss of $491.7 million, as restated (see page 4)). The
difference is primarily due to the write-off in 2005 of in-process R&D of
$815.0 million following the TKT acquisition.

Cash inflow from operating activities for the year to December 31, 2006
increased by 38% to $531.9 million (2005: $384.3 million). The net increase
resulted mainly from favourable movements in working capital, in particular the
timing of sales within the final quarter of 2006 coupled with a reduction in
the net tax paid of $48.5 million.

Cash and cash equivalents, restricted cash and short-term investments at
December 31, 2006 totaled $1,156.7 million (December 31, 2005: $694.0 million).
The increase in cash and cash equivalents during the year of $470.4 million was
primarily due to positive cash flows from Shire's operations, the sale of
product rights to Duramed for $63.0 million and proceeds from loans repaid by
IDB of $70.6 million, offset by purchases of property, plant and equipment
($100.3 million) and a milestone payment to Noven Pharmaceuticals Inc. (Noven)
on DAYTRANA's approval ($50.0 million).

Summary of Q4 2006

Revenues from continuing operations for the three months to December 31, 2006
increased by 7% to $497.0 million (2005: $464.9 million) with ELAPRASE and
DAYTRANA contributing $34.5 million to Q4 2006 sales.

Income from continuing operations (before income taxes and equity in earnings/
(losses) of equity method investees) for the three months to December 31, 2006
was $90.3 million (2005: $101.0 million).

Cash inflow from operating activities for the three months to December 31, 2006
was $188.8 million (2005: $155.0 million). This increase primarily resulted
from favourable movements in working capital.

2. Product sales

For the year to December 31, 2006 product sales increased by 16% to $1,535.8
million (2005: $1,327.7 million) and represented 86% of total revenues (2005:
83%).

Product Highlights

                            Sales         Sales         US Rx       US Market  
Product                      $M        Growth (2)    Growth (1)     Share (1)  
                                                         (2)                   
                                                                               
ADDERALL XR                     863.6     +18%           +8%           26%     
                                                                               
DAYTRANA                         25.1      n/a           n/a           2%      
                                                                               
CARBATROL                        68.3      -5%           -9%           42%     
                                                                               
PENTASA                         137.8      +1%           +2%           18%     
                                                                               
REPLAGAL(3)                     117.7      n/a           n/a           n/a     
                                                                               
ELAPRASE                         23.6      n/a           n/a           n/a     
                                                                               
XAGRID(4)                        53.3     +14%           n/a           n/a     
                                                                               
FOSRENOL                         44.8     -16%          +34%           9%      

(1) IMS Prescription Data - Product specific (December 2006).

(2) Compared to 2005.

(3) REPLAGAL was acquired as part of the TKT acquisition, which completed in
July 2005. Total sales for REPLAGAL, including pre-acquisition sales, for the
year ended 2005 were $94.6 million with total growth for the year ended 2006,
including pre-acquisition sales, of 24%. In 2005 total post-acquisition sales
were $41.3 million.

(4) Worldwide sales excluding US and Canada.

ADDERALL XR for the treatment of ADHD

ADDERALL XR is the leading brand in the US ADHD market with an average market
share of 26% in 2006 (2005: 25%). US ADHD market growth of 4% and the 1%
increase in average market share contributed to an 8% increase in US
prescriptions for ADDERALL XR for year to December 31, 2006 compared to the
same period in 2005.

Sales of ADDERALL XR for the year to December 31, 2006 were $863.6 million, an
increase of 18% compared to the same period in 2005 (2005: $730.8 million).
Product sales growth was significantly higher than prescription growth due
primarily to price increases in August 2005 and April 2006.

During October 2005 Shire filed a Citizen Petition with the FDA requesting that
the FDA require more rigorous bioequivalence testing or additional clinical
testing for generic or follow-on drug products that reference ADDERALL XR
before they can be approved. Shire received correspondence from the FDA in
April 2006 stating that, due to the complex issues raised requiring extensive
review and analysis by the FDA's officials, a decision cannot yet be reached by
the FDA. The FDA did not provide any guidance as to when that decision may be
reached.

On August 14, 2006 Shire and Barr announced that all pending litigation in
connection with Barr's Abbreviated New Drug Application (ANDA) and its attempt
to market generic versions of Shire's ADDERALL XR had been settled. As part of
the settlement, Barr entered into consent judgments and agreed to permanent
injunctions confirming the validity and enforceability of Shire's US Patents
Nos. 6,322,819 (the "819 Patent"), 6,601,300 (the "300 Patent") and 6,913,768
(the "768 Patent"). Barr has also admitted that any generic product made under
its ANDA would infringe the 768 patent. Under the terms of the settlement,
Barr will not be permitted to market a generic version of ADDERALL XR in the US
until April 1, 2009, except in certain limited circumstances, such as the
launch of another party's generic version of ADDERALL XR. No payments to Barr
are involved in the settlement agreement.

In January 2006, Shire settled its ADDERALL XR patent infringement lawsuits
with Impax. Under the terms of the settlement, Impax will be permitted to
market generic versions of ADDERALL XR in the US no later than January 1, 2010
and will pay the Company a royalty from those sales. In certain situations,
such as the launch of another generic version of ADDERALL XR, Impax may be
permitted to enter the market as the Company's authorized generic. No payments
to Impax are involved in the settlement agreement.

Litigation proceedings concerning Shire's ADDERALL XR patents are ongoing. 
Further information can be found in our filings with the US Securities and
Exchange Commission, including our Annual Report on Form 10-K for the year to
December 31, 2005 and our most recent Quarterly Report on Form 10-Q for the
period ended September 30, 2006. 

DAYTRANA for the treatment of ADHD

Following its launch in June 2006, DAYTRANA achieved a 2% share of the US ADHD
market by December 31, 2006. Sales for the year to December 31, 2006 were $25.1
million, a level of sales which triggered the first of three potential $25.0
million sales milestone payments to Noven. This milestone, which was paid on
February 14, 2007, has been capitalized as at December 31, 2006 and will be
amortized over 10 years. Net sales for 2006 were impacted by the redemption of
$14 million of coupons issued to support the product launch.

The addition of DAYTRANA, combined with growth in ADDERALL XR market share has
helped Shire grow its total share of the US ADHD market to 28% at December 31,
2006 compared to 26% (which included a 1% share relating to ADDERALL) at
December 31, 2005.

CARBATROL for the treatment of Epilepsy

US prescriptions for the year ending December 31, 2006 were down 9% compared to
the same period in 2005. This was primarily due to a 6% decline in the US
extended release carbamazepine prescription market. CARBATROL's US market share
remained at 42%.

Sales of CARBATROL for the year ending December 31, 2006 were $68.3 million, a
decrease of 5% compared to the same period in 2005 (2005: $72.1 million). The
fall in sales is due to the decrease in the extended release carbamezapine
market and a reduction of pipeline inventory in 2006 compared to stocking in
2005, offset by price increases in October 2005 and July 2006.

In July 2006 Impax deployed a sales force to begin promotion of CARBATROL under
a promotional services agreement for the US market signed in January 2006.

Patent litigation proceedings with Nostrum Pharmaceuticals, Inc. and Corepharma
LLC relating to CARBATROL are ongoing. Further information about the ongoing
proceedings relating to the Company's CARBATROL patents can be found in our
filings with the US Securities and Exchange Commission, including our Annual
Report on Form 10-K for the period ended December 31, 2005 and our most recent
Quarterly Report on Form 10-Q for the period ended September 30, 2006.

PENTASA for the treatment of Ulcerative Colitis

US prescriptions for the year ending December 31, 2006 were up 2% compared to
the same period in 2005 primarily due to a 4% increase in the US oral
mesalamine prescription market. PENTASA's US market share remained at 18%.

Sales of PENTASA for the year ending December 31, 2006 were $137.8 million, an
increase of 1% compared to the same period in 2005 (2005: $136.1 million).
Sales growth is marginally lower than prescription growth due to the lower
levels of pipeline stocking in 2006, partly offset by the impact of price
increases in January 2006 and November 2006.

REPLAGAL for the treatment of Fabry Disease

Sales for the year ending December 31, 2006 were $117.7 million, of which 88%
were in Europe and 12% in the rest of the world. Sales for REPLAGAL for the
year ending December 31, 2005 were $94.6 million, including pre-acquisition
sales of $53.3 million. This represents a like-for-like increase in sales of
24% which was due to greater European coverage by an increased number of sales
representatives and strong growth in the rest of the world market (excluding
the US).

ELAPRASE for the treatment of Hunter Syndrome

ELAPRASE was launched in the US in August 2006 and has had a strong start with
over 110 patients receiving treatment by the end of December 2006. In addition,
through the pre-approval process, over 100 patients were receiving treatment in
Europe by the end of the year. Sales reached $23.6 million by December 31,
2006.

XAGRID for the treatment of Thrombocythemia

Sales for the year ended December 31, 2006 were $53.3 million, an increase of
14% compared to the same period in 2005 (2005: $46.8 million). Expressed in
transaction currencies (XAGRID is primarily sold in Euros), sales increased by
13% due mainly to strong growth in France and Spain. In addition there was a
benefit of 1% from favorable exchange rate movements against the US dollar.

AGRYLIN sales in North America (US and Canada) were $7.5 million for the year
ended December 31, 2006 (2005: $46.0 million). This reduction was expected
following the approval of generic versions of AGRYLIN in the US market in April
2005.

FOSRENOL for the treatment of Hyperphosphatemia

US prescriptions for the year ending December 31, 2006 were up 34% compared to
2005 due to FOSRENOL increasing its average share of the total US phosphate
binding market to 9% (2005: 7%) and market growth of 9% over the same period.
FOSRENOL was launched in the US in January 2005.

US sales of FOSRENOL for the year ending December 31, 2006 were $40.2 million
(2005: $53.0 million). The decrease in net sales of 16% compared to
prescription growth of 34% is primarily due to destocking in 2006 compared to
significant stocking of higher strength formulations at the end of 2005.

An agreement with Abbott was signed in December 2006 for the co-promotion of
FOSRENOL in the US.  Abbott's US renal care sales team will co-promote FOSRENOL
with its own renal product ZEMPLAR. Shire's US sales force will also continue
to promote FOSRENOL.  This agreement began in Q1 2007, and will continue for a
term of five years.

European sales of FOSRENOL for the year ending December 31, 2006 were $4.6
million (2005: $0.5 million), giving total FOSRENOL sales worldwide of $44.8
million (2005: $53.5 million).

FOSRENOL has now been launched in Germany, France and a number of other
European countries. Launches will continue throughout 2007 in the EU including
the UK, Italy and Spain, subject to finalization of national licensing and
conclusion of pricing and reimbursement negotiations.

On October 18, 2006 Health Canada granted a marketing license application for
FOSRENOL. The Canadian launch is planned for Q2 2007.

3. Royalties

Royalty revenue remained constant at $242.9 million for the year to December
31, 2006 (2005: $242.9 million).

Royalty Highlights

Product              Royalties to Shire   Royalty (1)     Worldwide sales by  
                             $M              Growth      licensee (2) in 2006 
                                               %                              
                                                                  $M          
                                                                              
3TC                               150.9       -6%                        1,138
                                                                              
ZEFFIX                             34.8      14%(3)                        301
                                                                              
Other                              57.2        9%                          n/a
                                                                              
Total                             242.9        0%                             

(1) Compared with 2005.

(2) GSK

(3) The impact of foreign exchange movements has contributed +1% to the
reported growth.

3TC

Royalties from sales of 3TC for the year to December 31, 2006 were $150.9
million, a decrease of 6% compared to the prior year (2005: $159.8 million).

Shire receives royalties from GSK on worldwide 3TC sales. GSK's worldwide sales
of 3TC for the year to December 31, 2006 were $1,138 million, a decrease of 6%
compared to prior year (2005: $1,211 million). The nucleoside analogue market
for HIV has continued to grow, however competitive pressures within the market
have increased, leading to a decline in 3TC sales.

ZEFFIX

Royalties from sales of ZEFFIX for the year to December 31, 2006 were $34.8
million, an increase of 14% compared to the prior year (2005: $30.5 million).

Shire receives royalties from GSK on worldwide ZEFFIX sales. GSK's worldwide
sales of ZEFFIX for the year to December 31, 2006 were $301 million, an
increase of 13% compared to prior year (2005: $266 million). This increase was
mainly due to strong growth in the Korean, Japanese and Chinese markets.

OTHER

Other royalties are primarily in respect of REMINYL and REMINYL ER (known as
RAZADYNE and RAZADYNE ER in the US), a product marketed worldwide (excluding
the UK and the Republic of Ireland) by Janssen Pharmaceutical N.V. (Janssen),
an affiliate of Johnson & Johnson. Shire has the exclusive marketing rights in
the UK and the Republic of Ireland.

Sales of the REMINYL/ RAZADYNE range, for the symptomatic treatment of mild to
moderately severe dementia of the Alzheimer's type, continue to grow.

In June 2006 Janssen and Synaptech, Inc. filed a law suit against Barr for
infringement of their patent rights relating to RAZADYNE ER as a result of Barr
filing an ANDA with the FDA for a generic version of RAZADYNE ER. No court date
has been set.

Barr and other companies have filed ANDAs with the FDA for generic versions of
RAZADYNE and Janssen and Synaptech Inc. have filed law suits against some of
those ANDA filers. The court date for the first of these proceedings is May
2007.

4. Financial details

Cost of product sales

For the year to December 31, 2006 the cost of product sales was 16% of product
sales (2005: 16%). The cost of product sales for REPLAGAL in 2006 included a
$47.0 million adjustment in respect of acquired inventories (2005: $41.9
million). This fair value adjustment increased Shire's cost of product sales as
a percentage of sales for the year ended December 31, 2006 by 3% (2005: 3%).

For the year to December 31, 2006 cost of product sales included a charge of
$3.2 million for share based compensation under SFAS 123R (2005: $1.5 million).

Research and development (R&D)

R&D expenditure increased from $339.1 million in the year to December 31, 2005
to $386.9 million in the year to December 31, 2006, an increase of 14%. The
increase was primarily due to:

  * The addition of two significant R&D projects following the acquisition of
    TKT (ELAPRASE and GA-GCB); and
   
  * Upfront payments made to Duramed and Warren of $25.0 million and $5.5
    million, respectively.
   
Expressed as a percentage of total revenues, R&D expenditure was 22% for the
year to December 31, 2006 (2005: 21%). In both periods payments were made to
New River of $50 million for in-licensing VYVANSE. These payments have both
been expensed in accordance with Shire's accounting policy. The payments to New
River, Duramed and Warren in the year to December 31, 2006 totalled $80.5
million, equivalent to 5% of total revenues. In the year to December 31, 2005
the $50.0 million payment to New River was equivalent to 3% of total revenues.

For the year to December 31, 2006 R&D included a charge of $5.4 million for
share based compensation under SFAS 123R (2005: $2.9 million).

Selling, general and administrative (SG&A)

SG&A expenses increased from $655.5 million in the year to December 31, 2005 to
$835.4 million in the year to December 31, 2006, an increase of 27%. As a
percentage of product sales, SG&A expenses were 54% (2005: 49%).

The increase in SG&A expenses was expected, with additional expenditure
required for:

  * The promotion and launch of DAYTRANA (including an increase in the ADHD
    sales force);
   
  * The recruitment of a new GI sales force in the US;
   
  * The recruitment of new US and European sales forces to launch Elaprase; and
   
  * Pre-launch activities relating to the 2007 launches of DYNEPO, LIALDA and
    VYVANSE.
   
For the year to December 31, 2006 SG&A included a charge of $34.4 million for
share based compensation under SFAS 123R (2005: $24.8 million), representing 2%
of total revenue (2005: 1%).

Depreciation and amortization

The depreciation charge for the year to December 31, 2006 was $43.3 million
(2005: $29.2 million, including $6.5 million for impairments of property, plant
and equipment). The amortization charge for the year to December 31, 2006 was
$56.3 million (2005: $45.2 million). The increase in both depreciation and
amortization is primarily due to the inclusion of a full year's amortization
and depreciation charge in respect of assets acquired through the TKT
acquisition, together with the amortization of capitalized milestone payments
for DAYTRANA following its launch in June 2006.

Intangible asset impairment

The charge for intangible asset impairments for the year to December 31, 2006
was $1.1 million (2005: $5.6 million). The impairment charge for the year to
December 31, 2006 resulted from the decision to stop selling a non-core
product.

The impairment charge for the year to December 31, 2005 resulted from the
approval of generic versions of AGRYLIN and the decision not to support and
promote certain non-core products.

Integration costs

For the year to December 31, 2006 the Company incurred $5.6 million of costs
associated with the integration of the TKT business into the Shire group (2005:
$9.7 million). This included retention payments for key staff of $3.0 million,
IT costs of $1.2 million and other costs of $1.4 million.

Gain on sale of product rights

For the year to December 31, 2006 the Company recognized a pre-tax gain of
$63.0 million (2005: $nil) on the disposal of ADDERALL to Duramed for $63.0
million in cash.

Interest income

For the year to December 31, 2006 the Company received interest income of $50.5
million (2005: $35.3 million). This income primarily related to interest
received on Shire's cash balances. Interest income for the year ending December
31, 2006 is higher than for the year ending December 31, 2005 primarily as a
result of increases in US dollar interest rates.

Interest expense

For the year to December 31, 2006 the Company incurred interest expense of
$26.4 million (2005: $12.0 million).

In both years this expense primarily relates to a provision for interest, which
may be awarded by the Court in respect of amounts due to those ex-TKT
shareholders who have requested appraisal of the acquisition consideration
payable for their TKT shares. The trial date for the appraisal rights
litigation has been set for April 23, 2007. Further information can be found in
our filings with the US Securities and Exchange Commission, including our
Annual Report on Form 10-K for the year to December 31, 2005 and our most
recent Quarterly Report on Form 10-Q for the period ended September 30, 2006. 

Other income, net

For the year to December 31, 2006 other income totaled $9.5 million.  This
included $4.6 million of investment income, foreign exchange gains of $3.2
million and $3.8 million of other income, offset by impairments of long-term
investments of $2.1 million. 

For the year to December 31, 2005 other income totaled $9.9 million.  This
included $4.3 million of investment income, a gain on sale of
available-for-sale securities of $3.9 million, a gain on sale of the drug
formulation business of $3.6 million and $1.5 million of other income, offset
by impairments of long-term investments of $2.0 million and foreign exchange
losses of $1.4 million.

Taxation

The effective rate of tax for the year to December 31, 2006 was 26.8% (2005:
27.5%, after excluding the impact of the $815.0 million write-off of in-process
R&D in respect of the TKT acquisition). The effective rate has fallen by 0.7%
as a result of a reduction in deferred taxes offset by an increase in current
taxes as a result of additional tax contingencies of $187 million recognised in
relation to ongoing tax audits. The reduction in deferred taxes was primarily
due to the reversal of valuation allowances following changes in estimates as
to the realisation of certain deferred tax assets. Following this reversal of
valuation allowances the net deferred tax asset has increased to $261.0 million
at December 31, 2006 (December 31, 2005: $116.2 million). Realization of
deferred tax assets is dependent upon generating sufficient taxable income to
utilize such assets. Although realization of these assets is not assured, it is
more likely than not that the amount recognized will be realized.

Equity in earnings/(losses) of equity method investees

Net earnings of equity method investees of $5.7 million were recorded for the
year to December 31, 2006 (2005: net losses of $1.0 million). This comprised
earnings of $6.2 million from the 50% share of the antiviral commercialization
partnership with GSK in Canada (2005: $5.3 million), offset by losses of $0.5
million being the Company's share of losses in the GeneChem and EGS Healthcare
Funds (2005: losses of $6.3 million).

Unaudited US GAAP results for the years to December 31, 2006 and 2005
Consolidated Balance Sheets

                                                     December 31,    1 Adjusted
                                                                   and restated
                                                             2006              
                                                                   December 31,
                                                               $M              
                                                                           2005
                                                                               
                                                                             $M
                                                                               
                                                      ___________   ___________
                                                                               
ASSETS                                                                         
                                                                               
Current assets:                                                                
                                                                               
Cash and cash equivalents                                 1,126.9         656.5
                                                                               
Restricted cash                                              29.8          30.6
                                                                               
Short-term investments                                          -           6.9
                                                                               
Accounts receivable, net                                    310.8         329.9
                                                                               
Inventories                                                 131.1         136.0
                                                                               
Deferred tax asset                                          105.7          54.2
                                                                               
Prepaid expenses and other current assets                   106.0          98.1
                                                                               
                                                      ___________   ___________
                                                                               
Total current assets                                      1,810.3       1,312.2
                                                                               
Non current assets:                                                            
                                                                               
Investments                                                  55.8          50.2
                                                                               
Property, plant and equipment, net                          292.8         234.0
                                                                               
Goodwill                                                    237.4         225.6
                                                                               
Other intangible assets, net                                762.4         729.3
                                                                               
Deferred tax asset                                          155.3          62.0
                                                                               
Other non-current assets                                     12.4          42.9
                                                                               
                                                      ___________   ___________
                                                                               
Total assets                                              3,326.4       2,656.2
                                                                               
                                                      ___________   ___________
                                                                               
LIABILITIES AND SHAREHOLDERS' EQUITY                                           
                                                                               
Current liabilities:                                                           
                                                                               
Accounts payable and accrued expenses                       566.1         431.8
                                                                               
Liability to dissenting shareholders                        452.3         427.6
                                                                               
Other current liabilities                                   313.6         106.0
                                                                               
                                                      ___________   ___________
                                                                               
Total current liabilities                                 1,332.0         965.4
                                                                               
Non-current liabilities                                      52.1          43.5
                                                                               
                                                      ___________   ___________
                                                                               
Total liabilities                                         1,384.1       1,008.9
                                                                               
                                                      ___________   ___________
                                                                               

1 Retrospectively adjusted following the adoption of SFAS 123R, and restated
for the correction to the value ascribed to IPR&D acquired with the acquisition
of TKT, as explained on page 4.

Unaudited US GAAP results for the years to December 31, 2006 and 2005

Consolidated Balance Sheets (continued)

                                                     December 31,    1 Adjusted
                                                                   and restated
                                                             2006              
                                                                   December 31,
                                                               $M              
                                                                           2005
                                                                               
                                                                             $M
                                                                               
                                                      ___________   ___________
                                                                               
Shareholders' equity:                                                          
                                                                               
Common stock of 5p par value: 750 million                    43.7          42.7
shares authorized; and 506.7 million shares                                    
issued and outstanding (2005: 750 million                                      
shares authorized; and 495.7 million shares                                    
issued and outstanding)                                                        
                                                                               
Exchangeable shares: 1.3 million shares                      59.4         101.2
issued and outstanding (2005: 2.2 million)                                     
                                                                               
Treasury stock                                             (94.8)         (2.8)
                                                                               
Additional paid-in capital                                1,493.2       1,327.5
                                                                               
Accumulated other comprehensive income                       87.8          71.5
                                                                               
Retained earnings                                           353.0         107.2
                                                                               
                                                      ___________   ___________
                                                                               
Total shareholders' equity                                1,942.3       1,647.3
                                                                               
                                                      ___________   ___________
                                                                               
Total liabilities and shareholders' equity                3,326.4       2,656.2
                                                                               
                                                      ___________   ___________
                                                                               

1 Retrospectively adjusted following the adoption of SFAS 123R, and restated
for the correction to the value ascribed to IPR&D acquired with the acquisition
of TKT, as explained on page 4.

Unaudited US GAAP results for the 3 months and years to December 31, 2006 and
2005
Consolidated Statements of Operations

                            3 months to   1 Adjusted  12 months to   1 Adjusted
                           December 31,               December 31, and restated
                                   2006  3 months to          2006             
                                        December 31,               12 months to
                                     $M         2005            $M December 31,
                                                                               
                                                  $M                       2005
                                                                               
                                                                             $M
                                                                               
                            ___________  ___________   ___________  ___________
                                                                               
Revenues:                                                                      
                                                                               
Product sales                     427.6        397.5       1,535.8      1,327.7
                                                                               
Royalties                          61.1         61.8         242.9        242.9
                                                                               
Other revenues                      8.3          5.6          17.8         28.7
                                                                               
                            ___________  ___________   ___________  ___________
                                                                               
Total revenues                    497.0        464.9       1,796.5      1,599.3
                                                                               
                            ___________  ___________   ___________  ___________
                                                                               
Costs and expenses:                                                            
                                                                               
Cost of product sales              62.4         79.1         247.7        215.5
                                                                               
Research and development           82.9         85.9         386.9        339.1
                                                                               
Selling, general and              241.3        171.9         835.4        655.5
administrative                                                                 
                                                                               
Depreciation and                   27.3         24.3          99.6         74.4
amortization                                                                   
                                                                               
Intangible asset                    1.1          2.6           1.1          5.6
impairment                                                                     
                                                                               
Reorganization costs                  -            -             -          9.4
                                                                               
Integration costs                   1.7          6.2           5.6          9.7
                                                                               
In-process R&D write-off              -            -             -        815.0
                                                                               
Gain on sale of product               -            -        (63.0)            -
rights                                                                         
                                                                               
                            ___________  ___________   ___________  ___________
                                                                               
Total operating expenses          416.7        370.0       1,513.3      2,124.2
                                                                               
                            ___________  ___________   ___________  ___________
                                                                               
Operating income/(loss)            80.3         94.9         283.2      (524.9)
                                                                               
Interest income                    13.7          7.4          50.5         35.3
                                                                               
Interest expense                  (7.3)        (7.3)        (26.4)       (12.0)
                                                                               
Other income, net                   3.6          6.0           9.5          9.9
                                                                               
                            ___________  ___________   ___________  ___________
                                                                               
Total other income, net            10.0          6.1          33.6         33.2
                                                                               
                            ___________  ___________   ___________  ___________
                                                                               
Income/(loss) from                 90.3        101.0         316.8      (491.7)
continuing operations                                                          
before income taxes and                                                        
equity in earnings /                                                           
(losses) of equity method                                                      
investees                                                                      
                                                                               
Income taxes                     (21.9)       (29.9)        (84.9)       (88.8)
                                                                               
Equity in earnings/                 0.2        (1.1)           5.7        (1.0)
(losses) of equity method                                                      
investees                                                                      
                                                                               
                            ___________  ___________   ___________  ___________
                                                                               
Income/(loss) from                 68.6         70.0         237.6      (581.5)
continuing operations                                                          
                                                                               
Gain/(loss) from                      -        (1.0)          40.6          3.1
discontinued operations                                                        
(net of income tax expense                                                     
of $nil and $nil)                                                              
                                                                               
                             __________  ___________   ___________  ___________
                                                                               
Net income/(loss)                  68.6         69.0         278.2      (578.4)
                                                                               
                            ___________  ___________   ___________  ___________
                                                                               

1 Retrospectively adjusted following the adoption of SFAS 123R, and restated
for the correction to the value ascribed to IPR&D acquired with the acquisition
of TKT, as explained on page 4.

Unaudited US GAAP results for the 3 months and years to December 31, 2006 and
2005
Consolidated Statements of Operations (continued)

                            3 months to   1 Adjusted 12 months to   1 Adjusted
                           December 31,              December 31, and restated
                                   2006  3 months to         2006             
                                        December 31,              12 months to
                                                2005              December 31,
                                                                          2005
                                                                              
                            ___________  ___________  ___________  ___________
                                                                              
Earnings per share - basic                                                    
                                                                              
Income/(loss) from                13.6c        14.0c        47.2c     (116.2c)
continuing operations                                                         
                                                                              
Gain/(loss) on disposition            -       (0.2c)         8.1c         0.6c
of discontinued operations                                                    
                                                                              
                            ___________  ___________  ___________  ___________
                                                                              
Earning/(loss) per                13.6c        13.8c        55.3c     (115.6c)
ordinary share - basic                                                        
                                                                              
                            ___________  ___________  ___________  ___________
                                                                              
Earnings per share -                                                          
diluted                                                                       
                                                                              
Income/(loss) from                13.4c        13.9c        46.6c     (116.2c)
continuing operations                                                         
                                                                              
Gain/(loss) on disposition            -       (0.2c)         8.0c         0.6c
of discontinued operations                                                    
                                                                              
                            ___________  ___________  ___________  ___________
                                                                              
Earnings/(loss) per               13.4c        13.7c        54.6c     (115.6c)
ordinary share - diluted                                                      
                                                                              
                            ___________  ___________  ___________  ___________
                                                                              
Earnings/(loss) per ADS -         40.2c        41.1c       163.8c     (346.8c)
diluted                                                                       
                                                                              
                            ___________  ___________  ___________  ___________
                                                                              
Weighted average number of       No. of       No. of       No. of       No. of
shares:                          shares       shares       shares       shares
                                                                              
                               Millions     Millions     Millions     Millions
                                                                              
Basic                             502.5        501.7        503.4        500.2
                                                                              
Diluted                           510.3        504.1        509.3        500.2
                                                                              
                            ___________  ___________  ___________  ___________
                                                                              

1 Retrospectively adjusted following the adoption of SFAS 123R, and restated
for the correction to the value ascribed to IPR&D acquired with the acquisition
of TKT, as explained on page 4.

Unaudited US GAAP results for the 3 months and years to December 31, 2006 and
2005
Consolidated Statements of Cash Flows

                              3 months to  1 Adjusted 12 months to   1 Adjusted
                             December 31,             December 31, and restated
                                     2006 3 months to         2006             
                                             December              12 months to
                                       $M    31, 2005           $M December 31,
                                                                           2005
                                                   $M                          
                                                                             $M
                                                                               
                              ___________ ___________  ___________  ___________
                                                                               
CASH FLOWS FROM OPERATING                                                      
ACTIVITIES:                                                                    
                                                                               
Net income/(loss)                    68.6        69.0        278.2      (578.4)
                                                                               
Adjustments to reconcile net                                                   
income/(loss) to net cash                                                      
provided by operating                                                          
activities:                                                                    
                                                                               
Depreciation and                      1.3         0.8          4.8          3.5
amortization:                                                                  
                                     26.8        23.9         99.1         68.0
- in cost of product sales                                                     
                                                                               
- in other costs and                                                           
expenses                                                                       
                                                                               
Share based compensation             17.2         8.4         43.0         29.2
                                                                               
In-process R&D write-off                -           -            -        815.0
                                                                               
Write-down of long-term               2.0         3.1          3.8         14.1
assets                                                                         
                                                                               
Gain on sale of long-term           (0.5)           -        (0.3)        (3.9)
assets                                                                         
                                                                               
Gain on sale of drug                    -       (3.6)            -        (3.6)
formulation business                                                           
                                                                               
Equity in (earnings)/losses         (0.2)         1.1        (5.7)          1.0
of equity method investees                                                     
                                                                               
Gain on sale of product                 -           -       (63.0)            -
rights                                                                         
                                                                               
Loss/(gain) on disposition              -         1.1       (40.6)        (3.1)
of discontinued operations                                                     
                                                                               
Changes in operating assets                                                    
and liabilities, net of                                                        
acquisitions:                                                                  
                                                                               
Decrease/(increase) in                9.0      (46.0)         27.6       (79.9)
accounts receivable                                                            
                                                                               
Increase in sales deduction           7.2         4.2         24.8         18.6
accrual                                                                        
                                                                               
(Increase)/decrease in              (3.5)         9.9          7.2          8.6
inventory                                                                      
                                                                               
Decrease/(increase) in                4.2      (15.7)        (6.2)       (40.1)
prepayments and other                                                          
current assets                                                                 
                                                                               
(Increase)/decrease in other        (2.3)         0.1          0.7        (0.7)
assets                                                                         
                                                                               
Movement in deferred taxes        (147.4)      (12.0)      (142.4)         22.3
                                                                               
Increase in accounts and            201.9       114.8        297.0        122.9
notes payable and other                                                        
liabilities                                                                    
                                                                               
Increase/(decrease) in                4.5       (3.0)        (1.9)       (13.5)
deferred revenue                                                               
                                                                               
Returns on investments from             -           -          5.8          4.7
joint ventures                                                                 
                                                                               
Cash flows used in                      -       (1.1)            -        (0.4)
discontinued operations                                                        
                                                                               
                              ___________ ___________  ___________  ___________
                                                                               
Net cash provided by                188.8       155.0        531.9        384.3
operating activities(A)                                                        
                                                                               
                              ___________ ___________  ___________  ___________
                                                                               

1 Retrospectively adjusted following the adoption of SFAS 123R, and restated
for the correction to the value ascribed to IPR&D acquired with the acquisition
of TKT, as explained on page 4.

Unaudited US GAAP results for the 3 months and years to December 31, 2006 and
2005
Consolidated Statements of Cash Flows

                             3 months to   1 Adjusted 12 months to   1 Adjusted
                            December 31,              December 31,             
                                    2006  3 months to         2006 12 months to
                                         December 31,              December 31,
                                      $M         2005           $M         2005
                                                                               
                                                   $M                        $M
                                                                               
                             ___________  ___________  ___________  ___________
                                                                               
CASH FLOWS FROM INVESTING                                                      
ACTIVITIES:                                                                    
                                                                               
Movements in short-term                -         15.4          6.9        366.7
investments                                                                    
                                                                               
Movements in restricted            (0.3)        (0.5)          0.7        (0.8)
cash                                                                           
                                                                               
Purchase of subsidiary                 -       (14.4)        (0.8)    (1,114.0)
undertaking, net of cash                                                       
acquired                                                                       
                                                                               
Expenses of acquisitions               -       (13.4)            -       (37.5)
                                                                               
Purchase of long-term              (0.2)            -        (9.8)        (7.7)
investments                                                                    
                                                                               
Purchase of property, plant       (29.1)       (28.6)      (100.3)       (86.2)
and equipment                                                                  
                                                                               
Purchase of intangible             (6.0)        (0.4)       (58.8)       (20.5)
assets                                                                         
                                                                               
Proceeds from sale of                  -            -            -         10.1
long-term investments                                                          
                                                                               
Proceeds from sale of                  -            -          0.9          0.1
property, plant and                                                            
equipment                                                                      
                                                                               
Proceeds from sale of                0.4            -          0.4            -
intangible assets                                                              
                                                                               
Proceeds from sale of drug             -          0.6            -          0.6
formulation business                                                           
                                                                               
Proceeds from sale of                  -            -         63.0            -
product rights                                                                 
                                                                               
Proceeds from loan repaid              -            -         70.6            -
by IDB                                                                         
                                                                               
Loans made to IDB                                   -            -       (43.2)
                                                                               
Proceeds from sale of the              -            -            -         92.2
vaccines business                                                              
                                                                               
Returns of equity                      -            -          0.3          3.8
investments                                                                    
                                                                               
                             ___________  ___________  ___________  ___________
                                                                               
Net cash used in investing        (35.2)       (41.3)       (26.9)      (836.4)
activities(B)                                                                  
                                                                               
                             ___________  ___________  ___________  ___________

1 Retrospectively adjusted following the adoption of SFAS 123R

Unaudited US GAAP results for the 3 months and years to December 31, 2006 and
2005
Consolidated Statements of Cash Flows

                             3 months to   1 Adjusted 12 months to   1 Adjusted
                            December 31,              December 31,             
                                    2006  3 months to         2006 12 months to
                                         December 31,              December 31,
                                      $M         2005           $M         2005
                                                                               
                                                   $M                       $'M
                                                                               
                             ___________  ___________  ___________  ___________
                                                                               
CASH FLOWS FROM FINANCING                                                      
ACTIVITIES:                                                                    
                                                                               
Redemption of 2%                       -            -        (0.1)            -
convertible loan notes                                                         
                                                                               
Proceeds from exercise of           48.7          6.7         81.9         37.1
options                                                                        
                                                                               
Excess tax benefit of share            -          0.4            -          0.2
based compensation, charged                                                    
directly to equity                                                             
                                                                               
Payment of dividend                (9.8)        (9.4)       (32.4)       (28.5)
                                                                               
Payments to acquire               (23.6)        (2.5)       (92.0)        (2.5)
treasury stock                                                                 
                                                                               
                             ___________  ___________  ___________  ___________
                                                                               
Net cash provided by/(used          15.3        (4.8)       (42.6)          6.3
in) financing activities(C)                                                    
                                                                               
                             ___________  ___________  ___________  ___________
                                                                               
Effect of foreign exchange           2.8        (2.2)          8.0        (9.2)
rate changes on cash and                                                       
cash equivalents (D)                                                           
                                                                               
                             ___________  ___________  ___________  ___________
                                                                               
Net increase/(decrease) in         171.7        106.7        470.4      (455.0)
cash and cash equivalents                                                      
(A) +(B) +(C) +(D)                                                             
                                                                               
Cash and cash equivalents          955.2        549.8        656.5      1,111.5
at beginning of period                                                         
                                                                               
                             ___________  ___________  ___________  ___________
                                                                               
Cash and cash equivalents        1,126.9        656.5      1,126.9        656.5
at end of period                                                               
                                                                               
                             ___________  ___________  ___________  ___________
                                                                               

1 Retrospectively adjusted following the adoption of SFAS 123R

US GAAP results for the 3 months and years to December 31, 2006 and 2005

Selected Notes to the Unaudited US GAAP Financial Statements

(1) Earnings per share

                             3 months to   1 Adjusted 12 months to   1 Adjusted
                            December 31,              December 31, and restated
                                    2006  3 months to         2006             
                                         December 31,              12 months to
                                      $M         2005           $M December 31,
                                                                           2005
                                                   $M                          
                                                                             $M
                                                                               
                             ___________  ___________  ___________  ___________
                                                                               
Income/(loss) from                  68.6         70.0        237.6      (581.5)
continuing operations                                                          
                                                                               
Gain/(loss) on disposition             -        (1.0)         40.6          3.1
of discontinued operations                                                     
                                                                               
                             ___________  ___________  ___________  ___________
                                                                               
Numerator for basic and             68.6         69.0        278.2      (578.4)
diluted EPS                                                                    
                                                                               
                             ___________  ___________  ___________  ___________
                                                                               
Weighted average number of        No. of       No. of       No. of       No. of
shares:                           shares       shares       shares       shares
                                                                               
                                Millions     Millions     Millions     Millions
                                                                               
                             ___________  ___________  ___________  ___________
                                                                               
Basic                              502.5        501.7        503.4        500.2
                                                                               
Effect of dilutive shares:                                                     
                                                                               
Stock options                        7.1          2.0          5.3            -
                                                                               
Warrants                             0.7          0.4          0.6            -
                                                                               
                             ___________  ___________  ___________  ___________
                                                                               
Diluted                            510.3        504.1        509.3        500.2
                                                                               
                             ___________  ___________  ___________  ___________
                                                                               

1Retrospectively adjusted following the adoption of SFAS 123R, and restated for
the correction to the value ascribed to IPR&D acquired with the acquisition of
TKT, as explained on page 4

The share options and warrants not included in the calculation of the diluted
weighted average number of shares are shown below:

                       (1) 3 months  (1) 3 months  (1) 12 months  (2) 12 months
                        to December   to December    to December    to December
                           31, 2006      31, 2005       31, 2006       31, 2005
                                                                               
                      No. of shares No. of shares  No. of shares  No. of shares
                           Millions      Millions       Millions       Millions
                                                                               
                        ___________   ___________    ___________    ___________
                                                                               
Stock options                   2.6          11.2            7.7           20.7
                                                                               
Warrants                          -             -              -            1.3
                                                                               
                        ___________   ___________    ___________    ___________
                                                                               
                                2.6          11.2            7.7           22.0
                                                                               
                        ___________   ___________    ___________    ___________

 1. Not included as the exercise price exceeded the Company's average share
    price during the calculation period.
   
 2. Not included as the Company made a loss during the calculation period.
   
Unaudited US GAAP results for the 3 months to December 31, 2006 and 2005
Selected Notes to the US GAAP Financial Statements (continued)

(2) Analysis of revenues

                           3 months to  3 months to   3 months to   3 months to
                                                                   December 31,
                          December 31, December 31,  December 31,              
                                                                           2006
                                  2006         2005          2006    % of total
                                    $M           $M      % change       revenue
                                                                               
Net product sales:         ___________  ___________   ___________   ___________
                                                                               
CNS                                                                            
                                                                               
ADDERALL XR                      229.2        214.0           +7%           46%
                                                                               
ADDERALL                             -         12.1           n/a             -
                                                                               
DAYTRANA                          15.2            -           n/a            3%
                                                                               
CARBATROL                         17.6         17.3           +2%            5%
                                                                               
                           ___________  ___________   ___________   ___________
                                                                               
                                 262.0        243.4           +8%           54%
                                                                               
                           ___________  ___________   ___________   ___________
                                                                               
GI                                                                             
                                                                               
PENTASA                           38.3         42.3           -9%            8%
                                                                               
COLAZIDE                           2.4          2.1          +14%             -
                                                                               
                           ___________  ___________   ___________   ___________
                                                                               
                                  40.7         44.4           -8%            8%
                                                                               
                           ___________  ___________   ___________   ___________
                                                                               
GP                                                                             
                                                                               
XAGRID                            13.8         10.4          +33%            3%
                                                                               
FOSRENOL                          18.7         29.0          -36%            4%
                                                                               
CALCICHEW                         12.3         10.4          +18%            2%
                                                                               
REMINYL/REMINYL XL                 6.5          4.1          +59%            1%
                                                                               
SOLARAZE                           3.4          3.8          -11%            1%
                                                                               
                                                                             %%
                                                                               
VANIQA                             2.2          2.0          +10%             -
                                                                               
LODINE                             3.1          3.1             -            1%
                                                                               
                           ___________  ___________   ___________   ___________
                                                                               
                                  60.0         62.8           -4%           12%
                                                                               
                           ___________  ___________   ___________   ___________
                                                                               
HGT                                                                            
                                                                               
REPLAGAL                          31.2         25.4          +23%            6%
                                                                               
ELAPRASE                          19.3            -           n/a            4%
                                                                               
                           ___________  ___________   ___________   ___________
                                                                               
                                  50.5         25.4           n/a           10%
                                                                               
                           ___________  ___________   ___________   ___________
                                                                               
Other product sales               14.4         21.5          -33%            3%
                                                                               
                           ___________  ___________   ___________   ___________
                                                                               
Total product sales              427.6        397.5           +8%           87%
                                                                               
                           ___________  ___________   ___________   ___________
                                                                               
Royalty income:                                                                
                                                                               
3TC                               36.6         40.4           -9%            7%
                                                                               
ZEFFIX                             9.4          8.5          +11%            2%
                                                                               
Others                            15.1         12.9          +17%            3%
                                                                               
                           ___________  ___________   ___________   ___________
                                                                               
                                  61.1         61.8           -1%           12%
                                                                               
                           ___________  ___________   ___________   ___________
                                                                               
Other                              8.3          5.6          +48%            1%
                                                                               
                           ___________  ___________   ___________   ___________
                                                                               
Total revenues                   497.0        464.9           +7%          100%
                                                                               
                           ___________  ___________   ___________   ___________

Unaudited US GAAP results for the years to December 31, 2006 and 2005
Selected Notes to the US GAAP Financial Statements (continued)

(2) Analysis of          12 months to   12 months to  12 months to 12 months to
revenues (continued)                                                           
                         December 31,   December 31,  December 31, December 31,
Net product sales                                                              
                                 2006           2005          2006         2006
                                   $M             $M      % change   % of total
                                                                        revenue
                                                                               
                          ___________    ___________   ___________  ___________
                                                                               
CNS                                                                            
                                                                               
ADDERALL XR                     863.6          730.8          +18%          48%
                                                                               
ADDERALL                         23.6           43.1          -45%           1%
                                                                               
DAYTRANA                         25.1              -           n/a           1%
                                                                               
CARBATROL                        68.3           72.1           -5%           5%
                                                                               
                          ___________    ___________   ___________  ___________
                                                                               
                                980.6          846.0           16%          55%
                                                                               
                          ___________    ___________   ___________  ___________
                                                                               
GI                                                                             
                                                                               
PENTASA                         137.8          136.1           +1%           8%
                                                                               
COLAZIDE                          9.2            8.6           +7%           1%
                                                                               
                          ___________    ___________   ___________  ___________
                                                                               
                                147.0          144.7           +2%           9%
                                                                               
                          ___________    ___________   ___________  ___________
                                                                               
GP                                                                             
                                                                               
AGRYLIN/XAGRID                                                                 
                                                                               
N AMERICA                         7.5           46.0          -84%            -
                                                                               
ROW                              53.3           46.8          +14%           3%
                                                                               
FOSRENOL                         44.8           53.5          -16%           2%
                                                                               
CALCICHEW                        45.5           38.7          +18%           3%
                                                                               
REMINYL/REMINYL XL               21.5           13.5          +59%           1%
                                                                               
SOLARAZE                         13.2           12.5           +6%           1%
                                                                               
VANIQA                            7.9            6.3          +25%            -
                                                                               
LODINE                           12.6           12.6             -           1%
                                                                               
                          ___________    ___________   ___________  ___________
                                                                               
                                206.3          229.9          -10%          11%
                                                                               
                          ___________    ___________   ___________  ___________
                                                                               
HGT                                                                            
                                                                               
REPLAGAL*                       117.7           41.3           n/a           7%
                                                                               
ELAPRASE                         23.6              -           n/a           1%
                                                                               
                          ___________    ___________   ___________  ___________
                                                                               
                                141.3           41.3           n/a           8%
                                                                               
                          ___________    ___________   ___________  ___________
                                                                               
Other product sales              60.6           65.8           -8%           3%
                                                                               
                          ___________    ___________   ___________  ___________
                                                                               
Total product sales           1,535.8        1,327.7          +16%          86%
                                                                               
                          ___________    ___________   ___________  ___________
                                                                               
Royalty income:                                                                
                                                                               
3TC                             150.9          159.8           -6%           8%
                                                                               
ZEFFIX                           34.8           30.5          +14%           2%
                                                                               
Others                           57.2           52.6           +9%           3%
                                                                               
                          ___________    ___________   ___________  ___________
                                                                               
                                242.9          242.9             -          13%
                                                                               
                          ___________    ___________   ___________  ___________
                                                                               
Other                            17.8           28.7          -38%           1%
                                                                               
                          ___________    ___________   ___________  ___________
                                                                               
Total revenues                1,796.5        1,599.3           12%         100%
                                                                               
                          ___________    ___________   ___________  ___________
                                                                               

* REPLAGAL was acquired in the acquisition of TKT which was completed in July
2005. Total sales for REPLAGAL, including pre-acquisition sales for the year to
December 31, 2005 were $94.6 million. Including pre-acquisition sales for the
year to December 31, 2005, product sales growth was 24% for REPLAGAL.

Non GAAP reconciliation of income/(loss) from ongoing operations, net income
and numerator for diluted EPS for the 3 months and years to December 31, 2006 
and 2005

                            3 months to   1 Adjusted 12 months to   1 Adjusted
                           December 31,              December 31, and restated
                                         3 months to                          
                                   2006 December 31,         2006 12 months to
                                                                  December 31,
                                     $M         2005           $M             
                                                                          2005
                                                  $M                          
                                                                            $M
                                                                              
                             __________   __________   __________   __________
                                                                              
Non GAAP reconciliation of                                                    
income/(loss) from ongoing                                                    
operations(2)                                                                 
                                                                              
Income/(loss) from ongoing         90.3        101.0        316.8      (491.7)
operations(2)                                                                 
                                                                              
Add back:                                                                     
                                                                              
TKT in-process R&D                    -            -            -        815.0
write-off                                                                     
                                                                              
TKT cost of product sales             -         24.7         47.0         41.9
fair value adjustment                                                         
                                                                              
New River milestone                   -            -         50.0            -
payment                                                                       
                                                                              
New River upfront payment             -            -            -         50.0
                                                                              
Warren upfront payment                -            -          5.5            -
                                                                              
Duramed upfront payment               -            -         25.0            -
                                                                              
New listed holding company            -            -            -          4.5
costs                                                                         
                                                                              
Reorganization costs                  -            -            -          9.4
                                                                              
TKT integration costs               1.7          6.2          5.6          9.7
                                                                              
Gain on disposal of drug              -        (3.6)            -        (3.6)
formulation business                                                          
                                                                              
Gain on sale of product               -            -       (63.0)            -
rights                                                                        
                                                                              
                              _________    _________    _________    _________
                                                                              
Non GAAP adjustment to              1.7         27.3         70.1        926.9
income/(loss) from ongoing                                                    
operations                                                                    
                                                                              
                              _________    _________    _________    _________
                                                                              
Non GAAP income from               92.0        128.3        386.9        435.2
ongoing operations(2)                                                         
                                                                              
                              _________    _________    _________    _________
                                                                              
Non GAAP reconciliation of                                                    
net income and numerator                                                      
for diluted EPS                                                               
                                                                              
Net income/(loss)                  68.6         69.0        278.2      (578.4)
                                                                              
Non GAAP adjustment to              1.7         27.3         70.1        926.9
income/(loss) from ongoing                                                    
operations(2)                     (0.5)        (7.7)       (18.8)       (31.4)
                                                                              
Taxes on above adjustments                                                    
                                                                              
(Gain)/loss on disposition            -          1.0       (40.6)        (3.1)
of discontinued operations                                                    
                                                                              
                              _________    _________    _________    _________
                                                                              
Non GAAP adjustment to net          1.2         20.6         10.7        892.4
income/(loss) and                                                             
numerator for diluted EPS                                                     
                                                                              
                              _________    _________    _________    _________
                                                                              
Non GAAP net income and            69.8         89.6        288.9        314.0
numerator for non GAAP                                                        
diluted EPS                                                                   
                                                                              
                              _________    _________    _________    _________

1 Retrospectively adjusted following the adoption of SFAS 123R, and restated
for the correction to the value ascribed to IPR&D acquired with the acquisition
of TKT, as explained on page 4

2Income/(loss) from continuing operations before income taxes and equity in
earnings/ (losses) of equity method investees.Non GAAP reconciliation of repo
rted EPS for the 3 months and the years

to December 31, 2006 and 2005

                            3 months to   1 Adjusted 12 months to   1 Adjusted
                           December 31,              December 31, and restated
                                         3 months to                          
                                   2006 December 31,         2006 12 months to
                                                                  December 31,
                                                2005                          
                                                                          2005
                                                                              
                             __________   __________   __________   __________
                                                                              
Earnings/(loss) per               13.4c        13.7c        54.6c     (115.6c)
ordinary share-diluted                                                        
                                                                              
(Gain)/loss on disposition            -         0.2c       (8.0c)       (0.6c)
of discontinued operations                                                    
                                                                              
                             __________   __________   __________   __________
                                                                              
Diluted EPS from                  13.4c        13.9c        46.6c     (116.2c)
continuing operations                                                         
                                                                              
Change in denominator due             -            -            -         0.3c
to effect on dilution of                                                      
non GAAP adjustments(2)                                                       
                                                                              
                             __________   __________   __________   __________
                                                                              
                                  13.4c        13.9c        46.6c     (115.9c)
                                                                              
Add back:                                                                     
                                                                              
TKT in-process R&D                    -            -            -       162.5c
write-off                                                                     
                                                                              
TKT cost of product sales             -         4.9c         9.3c         8.4c
fair value adjustment                                                         
                                                                              
New River milestone                   -            -         9.8c            -
payment                                                                       
                                                                              
New River upfront payment             -            -            -        10.0c
                                                                              
Warren upfront payment                -            -         1.1c            -
                                                                              
Duramed upfront payment               -            -         4.9c            -
                                                                              
New listed holding company            -            -            -         0.9c
costs                                                                         
                                                                              
Reorganization costs                  -            -            -         1.8c
                                                                              
TKT integration costs              0.3c         1.2c         1.1c         1.9c
                                                                              
Gain on disposal of drug              -       (0.7c)            -       (0.7c)
formulation business                                                          
                                                                              
Gain on sale product                  -            -      (12.4c)            -
rights                                                                        
                                                                              
Taxes on above adjustments       (0.1c)       (1.5c)       (3.7c)       (6.3c)
                                                                              
                             __________   __________   __________   __________
                                                                              
Non GAAP - diluted EPS per        13.6c        17.8c        56.7c        62.6c
ordinary share                                                                
                                                                              
                             __________   __________   __________   __________
                                                                              
Non GAAP - diluted EPS per        40.8c        53.4c       170.1c       187.8c
ADS                                                                           
                                                                              
                             __________   __________   __________   __________
                                                                              
Total non GAAP adjustments         0.2c         4.1c         2.1c       178.2c
- diluted EPS per ordinary                                                    
share                                                                         
                                                                              
                            ___________  ___________  ___________  ___________
                                                                              

1 Retrospectively adjusted following the adoption of SFAS 123R, and restated
for the correction to the value ascribed to IPR&D acquired with the acquisition
of TKT, as explained on page 4

2 As the items added back to the net loss for the year to December 31, 2005
result in non GAAP net income for the year to December 31, 2005, the options
and warrants become dilutive under this measure and are therefore included in
the calculation of the denominator for non GAAP EPS.

                                   - ENDS -                                    






END

Kostenloser Wertpapierhandel auf Smartbroker.de
© 2007 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.